title: FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
abstract: FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre.
  
  
  
  This is a retrospective review of patients treated with FOLFIRINOX for pancreatic cancer at Princess Margaret Cancer Centre, between December 2011 and July 2014. The primary objective was to evaluate the efficacy and safety of FOLFIRINOX when used with dose modifications.
  
  
  
  One hundred two patients were identified; 66 metastatic and 36 locally advanced. Sixty-eight per cent of patients initiated treatment with a dose reduction. The median (95% CI) OS in the metastatic group was 13.1 (6.3-16.1) months with full dose and 12.9 (10.3-30.1) months with modified dose. The median (95% CI) OS in the locally advanced group was 11.1 (6.1-not reached) months with full dose and 23 (not reached-not reached) months with modified dose. The median (95% CI) PFS in the metastatic group was 6.2 (4.9-15.2) months with full dose and 8.7 (5.7-12.9) months with modified dose. The median (95% CI) PFS in the locally advanced group was 11.1 (3.1-not reached) months with full dose and 10.4 (6.8-not reached) months with modified dose. Grade 3/4 haematologic adverse events were observed in 43% of patients. Grade 3/4 non-haematologic adverse events were observed in 28% of patients. Patient well-being significantly improved from baseline to cycle 4 (P=0.002).
  
  
  
  Efficacy was achievable with dose-modified FOLFIRINOX in daily setting. The safety of FOLFIRINOX remains a concern with a high rate of grades 3 and 4 neutropaenia despite dose reduction.
authors.affiliation: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto M5G 2M9, Canada.
authors.forename: Muralidharan K
authors.initials: MK
authors.lastname: Chllamma
authors.affiliation: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto M5G 2M9, Canada.|The Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester M20 4BX, UK.
authors.forename: Natalie
authors.initials: N
authors.lastname: Cook
authors.affiliation: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto M5G 2M9, Canada.
authors.forename: Neesha C
authors.initials: NC
authors.lastname: Dhani
authors.affiliation: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto M5G 2M9, Canada.
authors.forename: Kazim
authors.initials: K
authors.lastname: Giby
authors.affiliation: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto M5G 2M9, Canada.
authors.forename: Anna
authors.initials: A
authors.lastname: Dodd
authors.affiliation: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto M5G 2M9, Canada.
authors.forename: Lisa
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto M5G 2M9, Canada.
authors.forename: David W
authors.initials: DW
authors.lastname: Hedley
authors.affiliation: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto M5G 2M9, Canada.|President, B.C. Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada.
authors.forename: Malcolm J
authors.initials: MJ
authors.lastname: Moore
authors.affiliation: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto M5G 2M9, Canada.
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Knox
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D018395:CA-19-9 Antigen / Q000032:analysis; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D057915:Drug Substitution; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D000077146:Irinotecan; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009864:Ontario; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011788:Quality of Life; D018805:Sepsis / Q000209:etiology; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000077146:Irinotecan; D017239:Paclitaxel; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin; D000093542:Gemcitabine